Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
3.38 | 0.01 (0.15%) |
| Exchange : | NASDAQ (US Dollar) |
| Ric Code : | ORMP |
| Volume : | 118,605 |
| Date : | 07-09-2020 |
* Minimum 20 minute delay See terms
–
Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]
Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin
Data Presented at the American Diabetes Association Scientific Session 2020 NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug [...]
Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June
Three Poster Presentations Granted to Discuss Oral Insulin Candidate ORMD-0801 NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug [...]
Oramed Patent in Canada Allowed for Oral Delivery of Proteins
NEW YORK, April 7, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Patent Office [...]
Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19
- Oral insulin FDA End-of-Phase 2 meeting expected this quarter - Strong balance sheet with roughly $50M in cash - NASH intermediate study data expected this quarter NEW YORK, April 1, 2020 /PRNewswire/ -- Oramed Pharmaceuticals [...]
Investors Tools